Celularity, Inc.
(NASDAQ : CELU)

( )
CELU PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Commercial Services » Miscellaneous Commercial Services
symbolcompany%chnglast%shortavg$volume
ETSYEtsy, Inc. -7.70%70.217.5%$464.09m
EFXEquifax, Inc. -2.77%191.532.0%$228.34m
CRLCharles River Laboratories International, Inc. -3.33%223.554.4%$151.82m
FLTFLEETCOR Technologies, Inc. -2.63%232.483.8%$138.65m
CPRTCopart, Inc. -2.12%108.154.4%$135.21m
CDKCDK Global, Inc. -0.07%54.302.4%$131.54m
CHGGChegg, Inc. -2.33%17.9915.1%$121.47m
BAHBooz Allen Hamilton Holding Corp. 4.73%84.922.1%$92.55m
CLVTClarivate Plc -3.89%14.090.0%$69.68m
GGenpact Ltd. 0.10%42.317.1%$63.83m
PAGSPagSeguro Digital Ltd. -5.98%13.360.0%$63.36m
MRVIMaravai Lifesciences Holdings, Inc. -4.43%34.110.0%$59.88m
BFAMBright Horizons Family Solutions, Inc. -2.00%86.181.4%$59.22m
MEDPMedpace Holdings, Inc. -0.30%133.321.0%$55.20m
SYNHSyneos Health, Inc. -1.27%70.560.0%$52.57m

Company Profile

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.